Notably, recent studies have shown that engineered VSV vectors, such as VSVΔM51, can drive CD8+ T cell-mediated tumor regression not only through direct infection of tumor cells but also by targeting non-tumor stromal cells within the TME (36). Here, CD8A is linked to neoplasm.